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ORIGINAL ARTICLE
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Abstract

2

Marfan syndrome (MFS) is an autosomal dominant genetic disorder caused by

3

complications, such as dilation, dissection and rupture, are the leading causes of MFS‐
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mutations in the FBN1 gene. Although many peripheral tissues are affected, aortic
related mortality. Aberrant TGF‐beta signalling plays a major role in the pathophysiology of MFS. However, the contributing mechanisms are still poorly understood. Here,
we aimed at identifying novel aorta‐specific pathways involved in the pathophysiology
of MFS. For this purpose, we employed the Fbn1 under‐expressing mgR/mgR mouse
model of MFS. We performed RNA‐sequencing of aortic tissues of 9‐week‐old mgR/
mgR mice compared with wild‐type (WT) mice. With a false discovery rate <5%, our
analysis revealed 248 genes to be differentially regulated including 20 genes previously unrelated with MFS‐related pathology. Among these, we identified Igfbp2, Ccl8,
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Spp1, Mylk2, Mfap4, Dsp and H19. We confirmed the expression of regulated genes by
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quantitative real‐time PCR. Pathway classification revealed transcript signatures
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cardiomyopathy. Furthermore, our immunoblot analysis of aortic tissues revealed
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involved in chemokine signalling, cardiac muscle contraction, dilated and hypertrophic
altered regulation of pSmad2 signalling, Perk1/2, Igfbp2, Mfap4, Ccl8 and Mylk2
protein levels in mgR/mgR vs WT mice. Together, our integrative systems approach
identified several novel factors associated with MFS‐aortic‐specific pathophysiology
that might offer potential novel therapeutic targets for MFS.
KEYWORDS

Chemokine signalling, Igfbp2 signalling, Marfan syndrome, Mfap4, mgR/mgR, RNA-sequencing,
Spp1, TGF-beta signalling, Transcriptomics

1 | INTRODUCTION

skeleton, lung, skin and dura.1 The major complication is aortic dissection, which generally occurs in the presence of aortic root dilata-

Marfan syndrome (MFS) is an inherited autosomal connective tissue

tion. In MFS, the extracellular matrix undergoes remodelling with

disorder caused by mutations in an extracellular matrix protein, fib-

increase in aortic stiffness and progressive weakening of the aortic

rillin‐1 (FBN1), with manifestations in the cardiovascular system, eye,

wall leading to aortic dissection.

---------------------------------------------------------------------------------------------------------------------------------------------------------------------This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2019 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
2526

|

wileyonlinelibrary.com/journal/jcmm

J Cell Mol Med. 2019;23:2526–2535.

BHUSHAN

|

ET AL.

2527

Extensive research has been conducted using mouse models with

und Soziales in Berlin (LaGeSo Reg. No. 0024/14). Mice were sacri-

mutant fibrillin‐1 (Fbn1) that develop MFS‐like aortopathy despite

ficed; the ascending aortas and arch of the mgR/mgR homozygous

normal aortic elastogenesis.2–4 Two mice models, Fbn1C1039G/+ and

and WT animals were isolated and pooled for subsequent RNA

mgR/mgR with different degrees of MFS pathologies, have fre-

expression analysis.

quently been used in MFS studies.3–6 In the Fbn1C1039G/+ model, it
has been observed that 90% of animals develop the variable severe
phenotype and ~5% of animals die by 8 months of age as a result of

2.2 | Van Giesson staining

aortic aneurysms.5 On contrary, the mgR/mgR (hypomorphic) model

Aortic architecture was assessed using elastic van Giesson staining

produces ~20% normal fibrillin1 that develops a severe form of MFS

kit from Sigma‐Aldrich, following the manufacturer's instructions.

with an earlier onset and an average survival of 2.5 months.2,7
Previous research has suggested that the pathophysiology of MFS
can be explained by ongoing abnormalities in TGF‐beta signalling that

2.3 | RNA‐sequencing analysis

lead to progressive destabilization of the aortic wall and it has been

Total RNA was extracted from WT and mgR/mgR homozygous ani-

suggested that fibrillin‐1 interacts with latent TGF‐beta binding pro-

mals (9 weeks old animals) using the RNeasy mini kit (Qiagen). Library

teins (LTBPs) to restrict TGF‐beta activation.8,9 Hence, the deficiency

preparation was done using the TruSeq RNA Library Preparation Kit

of fibrillin‐1 in MFS promotes the release and activation of TGF‐beta.

v2 (Illumina) following the manufacturer's instructions. An Illumina

Several studies have shown that there is an increased abundance of

HiSeq 2500 sequencing device was used to perform the high

TGF‐beta in MFS.8,10 In addition, non‐canonical TGF‐beta signalling

throughput sequencing, to generate 65‐75 million reads of 50‐bp

pathway (extracellular signal‐regulated kinase [ERK] 1 and 2) has also

paired‐end reads, with a mean insert size of 150 bp. The reads were

been shown to promote aortic aneurysms in Marfan mice.11 TGF‐beta

mapped to Mus musculus genome build (mm9) using TopHat2.16

neutralizing antibodies (1D11) and Losartan (an angiotensin II type 1

DESeq217 was used for differential expression analysis with a false

receptor [AT1] antagonist) have been shown to decrease TGF‐beta

discovery rate of 0.05% (FDR).

signalling in Marfan mouse models. Furthermore, aortic extracts containing elastin/fibrillin fragments with GxxPG motifs significantly
increased macrophage chemotaxis.12,13 Subsequent treatment of Mar-

2.4 | qRT‐PCRs

fan mice with a neutralizing antibody (BA4 ‐ anti‐elastin, monoclonal

Freshly dissected aortic tissues were snap‐frozen in liquid nitrogen. Fro-

antibody) decreased macrophage chemotaxis, inflammation and

zen tissues were pulverized and RNA was isolated using Qiagen RNeasy

degeneration of the vessel architecture.12

Mini kit following the manufacturer's instructions. For reverse transcrip-

Overall, in the last decade, the leading hypothesis has been that

tion, 1 microgram of RNA was used for conversion into cDNA using the

TGF‐beta induction is a major driver of Marfan disease progression.

RevertAid H minus cDNA Synthesis Kit (ThermoFisher Scientific). Real‐

This assumption was recently challenged by selectively deleting the

time PCR was performed on the Applied Biosystems 7900HT real‐time

TGF‐type‐II receptor in MFS mice (Fbn1C1039G/+) suggesting that

PCR machine as described previously.18 Gapdh was used as endoge-

increased TGF‐beta in MFS may not be the sole cause of MFS aor-

nous control. Refer to Data S1 for qPCR primers.

topathy.14 Consequently, these results suggest that there may be
previously unrecognized mechanisms, by which MFS disease progression is regulated and potential etiologies of MFS need further
examination.

2.5 | Western blots
Aortic samples were homogenized using FastPrep®‐24 Classic instru-

With an aim to gain insight into the molecular mechanisms and

ment for 20 seconds. Protein isolation was done using the QIAGEN All-

novel transcripts governing the progression of disease in MFS, we

Prep DNA/RNA/Protein Mini Kit, following the manufacturer's

performed RNA‐sequencing of aortic tissues from Marfan (mgR/mgR)

instructions, in the presence of protease and phosphatase inhibitors.

vs WT mice and identified several new factors associated with Mar-

Proteins were quantified using the Pierce BCA kit. Proteins (30 μg)

fan‐induced aortic disease progression.

were loaded on 10% SDS‐PAGE gels and transferred onto nitrocellulose
membranes. After blocking (3% milk in 0.1% PBS‐T), membranes were

2 | MATERIALS AND METHODS
2.1 | Animal experiments and isolation of ascending
aortas from mice
Heterozygous Fbn1 underexpressing mice (25) were mated to gener-

incubated with corresponding primary antibodies overnight at 4°C.
Immunoreactive proteins were detected using ECL Plus (GE Healthcare,
Buckinghamshire, UK). Refer to Data S1 for antibody details.

2.6 | Pathway classification

ate homozygous mgR/mgR and WT mice. Genotyping was performed

The gene functional annotation was performed using the DAVID

as previously described.15 Mice were maintained under pathogen‐

functional annotation tool19 (https://david.ncifcrf.gov/) followed by

free conditions, and the ethical guidelines for animal work and the

KEGG pathway analysis with an ease score of 0.03 and gene count

animal experiments were approved by the Landesamt für Gesundheit

of 5 genes per pathway.
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and identified 23 genes to be com-

monly regulated between the two datasets (Figure 1C, Table S4).
Interestingly, 225 genes were exclusively regulated in our dataset

3.1 | Differential gene regulation in the aorta of
WT vs mgR/mgR mice

(Table S5), while 126 genes were exclusively regulated in the previously published microarray dataset15 (Table S6). Furthermore, we

To identify novel factors and to gain insight into the molecular

compared our RNA‐sequencing dataset to other aneurysms such as

mechanisms underlying MFS, we employed mgR/mgR mice compar-

angiotensin II infused ‐ apolipoprotein deficient mouse model of

ing them with their WT littermates. First, we performed Van Giesson

abdominal aortic aneurysms (AAA, 17 weeks old aortas)21 and found

staining to assess the elastic architecture of the aortic tissue and we

36 genes to be common regulated across both datasets (Table S7,

found the elastic fibres to be fragmented in the mgR/mgR mice com-

Figure S3).

pared to WT mice (Figure 1A), a phenomenon commonly seen in
MFS.2,20
Next, we performed RNA‐sequencing of aortic tissues from
homozygous mgR/mgR vs WT mice. Our analysis revealed that 248

3.2 | Validation of selected transcripts by qPCR and
Western blotting

genes were differentially regulated between the two groups (Fig-

We selected and validated the genes randomly (Lrrc17, Gxylt2, Mfs-

ure 1B, Table S1), with 144 genes being up‐regulated and 104 being

d2a, Scube and Ank2) and based on their role in aneurysms

down‐regulated in WT vs mgR/mgR mice (Table S1). Importantly, our

(Mmp12, Spp1, Ctss) or cardiovascular complications (Mfap4, Igfbp2)

analysis revealed 20 transcripts previously unknown to be differen-

or inflammatory signalling pathways (Ccls and Ccrs). Our analysis

tially expressed in the aorta of MFS mice (Table S2).

revealed that many genes enriched in chemokine signalling (Ccl8,

Gene ontology (GO) analysis of the RNA‐sequencing data

Ccr5, Ccl9, Ccl6, Ccl7, Ccl2 and Ccl5) were highly induced in mgR/

revealed the enrichment of gene signatures in GO terms, such as

mgR aortic tissues (Figure 2B,D‐G and Figure S1). Another novel

adrenergic signalling in cardiomyocytes, dilated and hypertrophic car-

candidate gene identified from our sequencing analysis, Igfbp2, was

diomyopathy (HCM), chemokine signalling, cardiac muscle contrac-

found to be highly up‐regulated across independent biological repli-

tion

cates, suggesting that this might be a potential factor for MFS (Fig-

and

calcium

signalling

pathway,

that

are

relevant

to

cardiovascular complications and MFS (Table 2, Table S3).

ure 2A). Other highly up‐regulated candidates of interest were

We then compared our RNA‐sequencing dataset (9 weeks old

Spp1, Ctss, Cd55, Cd53, Lmod2, Irf7, Chrdl1, Tmem176b, Lgals3,

aortas, mgR/mgR mice) to a published microarray dataset (6 weeks

MMP12 and H19 LncRNA in mgR/mgR compared to WT mice

F I G U R E 1 RNA‐sequencing analysis of
WT vs mgR/mgR aorta. A, Verhoeff‐van
Gieson staining in wild‐type (WT) vs mgR/
mgR mouse. Van Gieson staining was
performed on aortas isolated from wild‐
type and mgR mice. Increased elastin
fragmentation and breaks were observed
in Marfan mice, compared to wild‐type. B,
Differential expression of genes by RNA‐
sequencing analysis in WT vs mgR/mgR
aortas (9 wk) animals. Heatmap depicting
the Log2 FKPM values of significantly
regulated genes (P < 0.05). The red colour
indicates the low expression of genes and
white indicates the high expression of
genes. C, Comparison of our RNA‐
sequencing data to published microarray
(Schwill, Seppelt et al. 2013). Our
comparison identified, 23 genes to be
commonly regulated between both and
225 genes to be exclusively regulated in
our dataset and 126 genes exclusive to
Schwill, Seppelt dataset
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F I G U R E 2 Validation of up‐regulated genes from RNA‐sequencing data. A‐E, qPCRs were performed between WT vs mgR/mgR aortas for
the up‐regulated genes from RNA‐sequencing data. Fold changes were calculated and Gapdh was used as normalizing control. Data were
validated across n = 3 different biological replicates. Each replicate is derived from three pooled WT vs mgR tissues (11 weeks old)
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(Figure 2C,H,I and Figure S1). In addition, we also identified and

be a crucial therapeutic target in MFS.26 Here, we speculate that the

validated a set of down‐regulated genes by qPCR, such as Lrrc17,

induced Igfbp2 levels in mgR/mgR mice could be crucial in regulating

Mfap4, Ncam1, Gxylt2, Mfsd2a, Scube3, Ank2, Dsp, Myh10, Xirp,

pERK1/2 levels in MFS and this needs further investigation.

Smoc1, Chsy3, Adamts17, ppp1R36, Mylk2, Gucy1b3 and Abcc9 (Fig-

Furthermore, Mfap4 was highly down‐regulated in mgR/mgR

ure 3 and Figure S2). The most significantly up‐ and down‐regu-

mice. Mfap4 is an extracellular glycoprotein that specifically binds

lated genes from our RNA‐sequencing data are provided as

tropoelastin, fibrillin‐1 and fibrillin‐2.27 It is expressed in elastic tis-

Table 1. We further assessed the protein levels of key genes iden-

sues, such as aorta, skin and lung, and is localized to elastic fibres of

tified by RNA‐sequencing. pSMAD2 and pErk1/2 signalling path-

these tissues.28–30 In dermal fibroblasts, MFAP4 interacts directly

ways were induced in mgR/mgR compared to WT mice (Figure 4A,

with fibrillin‐1 and plays a crucial role in microfibril development and

B). Furthermore, we demonstrated that Igfbp2 and Ccl8 protein

maintenance of ECM proteins.31 In mgR/mgR hypomorphic animals,

levels are induced (Figure 4C,E) and Mfap4 protein levels are

Fbn1 levels are low (~20% normal Fbn1 produced) and this corre-

decreased in mgR/mgR compared to WT mice (Figure 4D), which

sponds with low level of expression of Mfap4 in our data (RNA‐

correlates with our aortic RNA‐sequencing data. However, we

sequencing, qPCR and Western), suggesting a possible important

found Mylk2 protein levels to be increased (Figure 4F), contrary to

mechanistic role of Mfap4‐fibrillin‐1 interaction in MFS. However,

decreased mRNA levels in mgR/mgR compared to WT mice (Fig-

MFAP4 protein levels were found to be up‐regulated in Marfan

ure 3E).

patients,32 suggesting there could be differential regulation of
MFAP4 in different disease model systems or between species. Our
results on Mfap4 shed light on a potentially crucial regulator in MFS

4 | DISCUSSION

that needs further investigation.
We identified different chemokines to be highly up‐regulated in

In this study, we set out to identify novel differentially expressed

MFS (Figure 2D‐G). Medial necrosis and presence of inflammatory

genes during MFS in mgR/mgR aortas using RNA‐sequencing. Our

cells is well known in MFS. T cells (CD8+ and CD4+) have been

analysis revealed many previously unknown genes to be significantly

shown in adventitia of MFS aortas, emphasizing a crucial role of

regulated in mgR/mgR mice.

immune cells in both medial and adventitial layers of MFS aorta.33

The predominant paradigm of MFS pathophysiology in recent

Previously, studies have reported inflammatory genes to be involved

years has focussed on alterations of TGF‐beta signalling. Moreover,

in both mouse and human AAA.15,21,34 Among the chemokines identi-

high levels of circulating TGF‐beta were observed in Marfan mouse

fied in our data, Ccl8 was highly up‐regulated at both RNA (in RNA‐

models and patients, suggesting it is an important factor involved in

sequencing, qPCRs datasets) and protein levels. Apart from Ccl8, we

22,23

Most of the treatment regimens adopted have been to

identified Ccr5, Ccl5, Ccl2, Ccl7 and Ccl9, to be highly up‐regulated in

antagonize TGF‐beta signalling with neutralizing antibodies or Losar-

mgR/mgR mice. Ccl8 was also shown to be induced during AAA in

tan. However, more recent literature demonstrated that the deletion

mice.21 The role of IL6‐STAT3 signalling in contributing to aneurysm

of the TGF‐beta receptor II (Tgfbr2) increases the aortopathy in Mar-

dilation has been shown in mgR/mgR Marfan model.35 In MFS

fan animals, thus suggesting a complicated role of TGF‐beta sig-

patients, inflammation correlated with aortic disease, emphasizing the

nalling in MFS7,14 and also the possibility of other potential

crucial role of inflammatory signalling in aortic disease progression.33

regulators and mechanisms underlying the MFS phenotype.

It is known that defective fibrillin‐1 in MFS leads to impaired collagen

MFS.

To this extent, one of our novel findings is the regulation of Igf-

and network organization. This might lead to further collagen damage

bp2, which was significantly induced in mgR/mgR vs WT aortas in

and the release of degradation products that could possibly activate

our RNA‐ sequencing, qPCR and immunoblotting data. Igfbp2, a

inflammatory pathways.33 However, in Fbn1C1039G/+ Marfan model

secreted protein, belongs to a class of insulin like growth factor

the anti‐inflammatory therapy did not show beneficial effect on aortic

binding proteins (Igfbp1‐6), which bind to IGF1, IGF2 and insulin and

dilatation, suggesting a complex role of inflammation in different

signal via IGF1R, IGF‐IIR/M6P and insulin receptors, thus transducing

MFS model systems.36 Overall, it is unclear, if inflammation is the

the signal to the nucleus, followed by transcriptional activation of

cause or the consequence of aortic dilation and its role in MFS is not

specific genes to promote proliferation and differentiation. There

clearly understood. Collectively, our study reveals the importance of

have been conflicting reports about the role of Igfbp2 in cancers, as

several inflammatory genes that can be potential targets for novel

there is evidence supporting it to be both a tumour suppressor and

anti‐inflammatory therapeutics.

24

In glioma cells, Igfbp2 promotes

We also found Spp1, Mmp12 and Ctss to be significantly up‐

pERK1/2 phosphorylation via integrin β1, thus regulating cell prolifer-

regulated in mgR/mgR mice. Spp1 is a multifunctional phosphoprotein,

ation and invasion.25 It is known that pERK1/2 levels are induced in

expressed in various cell types and a known biomarker for cardiovas-

MFS mice and it has been proposed that abolishing pERK1/2 levels

cular diseases.6,37 Elevated Spp1 levels have been observed in circula-

an oncogene in different cancers.

11,20

could be a potential therapy towards MFS.

tion in different cancers, autoimmune disease and AAA. Spp1 has

In addition, it was shown that ERK1/2 signalling is limited to non‐

been shown to be involved in the regulation of chronic inflammation

myocyte compartment of MFS mouse heart and upon pressure over-

and recruitment of T cell and macrophages and regulates cytokine pro-

load, it contributes to cardiomyopathy, emphasizing ERK signalling to

duction in macrophages and T cells.38 The levels of OPN have been
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F I G U R E 3 Validation of down‐regulated genes from RNA‐sequencing data. A‐G, qPCR was performed between WT vs mgR/mgR aortas for
the down‐regulated genes from RNA‐ sequencing data. Fold changes were calculated and Gapdh was used as a normalizing control. Data were
validated across n = 3 or n = 2 different biological replicates. Each replicate is derived from three pooled WT vs mgR tissues (11 weeks old)
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T A B L E 1 Genes significantly up‐ or down‐regulated in mgR/mgR
aortic aneurysms both in RNA‐sequencing and qPCR datasets

ET AL.

found to be elevated in AAA patients (both in plasma and aortic wall)
and it may drive AAA formation.39 In addition, the local application of

Gene name

RNA‐seq and qPCR (in mgR/mgR)

P‐value

osteopontin enhanced vascular healing by decreasing the calcification

Igfbp2

Up

5.00E‐05

and maintaining the luminal integrity in rabbit thoracic aortas.40 In

Mfap4

Down

5.00E‐05

addition, a single SNP in TgfbrII had altered Spp1 secretion after

Tmem176b

Up

0.00065

Irf7

Up

5.00E‐05

Ccl8

Up

5.00E‐05

Ccl6

Up

0.00025

H19

Up

2.00E‐04

Ccl9

Up

0.00015

Spp1

Up

0.00045

Ctss

Up

5.00E‐05

Myh10

Down

0.00035

significantly up‐regulated in mgR/mgR mice. H19 is a conserved and

Lrrc17

Down

5.00E‐05

imprinted lncRNA having many biological functions in different dis-

Scube3

Down

5.00E‐05

eases. Increased levels of H19 are associated with increased risk of

Gxylt2

Down

5.00E‐05

coronary artery disease in patients.44 In addition, H19 was induced

Ncam1

Down

5.00E‐05

in heart failure patients.45 H19 in association with miR‐675 axis was

Mfsd2a

Down

0.00015

shown to regulate cardiomyocyte apoptosis and diabetic cardiomy-

adjusting for multiple testing.41 However, the mechanistic regulation
of Spp1 in Marfan aortic aneurysms is not clear. It is known that the
complex pathogenesis of MFS involves an imbalance in expression of
matrix metalloproteinases (MMPs) and tissue inhibitors of MMP activity.42 More specifically, Mmp2, Mmp9 and Mmp12 have been shown
to be up‐regulated in mgR/mgR mice.43 We identified the same trend
in Mmp12 expression. These results emphasize the importance of
Spp1, Ctss and Mmp12 in mgR/mgR disease progression.
Apart from coding genes, we also found the H19 LncRNA to be

opathy.46,47 The same axis (H19‐miR‐675) is reported to function as
a negative regulator of cardiomyocyte hypertrophy in mice.48

F I G U R E 4 Protein validations of
identified genes from RNA-sequencing
data by Western blots. A) pSmad2 and B)
pErk1/2 protein levels were induced in
mgR/mgR aortic tissues compared to WT
(11 weeks old animals). Up‐regulation of C)
Igfbp2, E) Ccl8 and F) Mylk2 protein levels
and Down‐regulation of D) Mfap4 protein
levels in mgR/mgR aortic tissues compared
to WT. Protein lysates were harvested as
described in methods sections. Gapdh or
Hsp60 was used as a loading control
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T A B L E 2 KEGG pathway analysis of differentially regulated genes from RNA‐sequencing data
Term

P‐value

Genes

Adrenergic signalling in cardiomyocytes

0.00026

Tnnt2, Actc1, Adcy7, Pln, Scn4b, Myh7, Myh6, Tnni3, Scn5a

Dilated cardiomyopathy

0.00042

Tnnt2, Actc1, Adcy7, Pln, Mybpc3, Ttn, Tnni3

Focal adhesion

0.00072

Myl7, Lamc3, Mylk3, Mylk4, Mylk2, Mylpf, Actn2, Mapk10, Col4a6, Spp1

Cardiac muscle contraction

0.00210

Tnnt2, Actc1, Cox6a2, Myh7, Myh6, Tnni3

cAMP signalling pathway

0.00858

Fos, Htr1b, Adcy7, Chrm2, Gria1, Pln, Mapk10, Tnni3

Gastric acid secretion

0.01023

Kcnj15, Adcy7, Mylk3, Mylk4, Mylk2

cGMP‐PKG signalling pathway

0.01252

Irs2, Irs3, Adcy7, Pln, Mylk3, Mylk4, Mylk2

Regulation of actin cytoskeleton

0.01284

Myl7, Chrm2, Mylk3, Mylk4, Mylk2, Mylpf, Actn2, Fgf12

Hypertrophic cardiomyopathy (HCM)

0.01404

Tnnt2, Actc1, Mybpc3, Ttn, Tnni3

Calcium signalling pathway

0.01955

Adcy7, Tnnc2, Chrm2, Pln, Mylk3, Mylk4, Mylk2

Chemokine signalling pathway

0.02828

Adcy7, Ccr5, Ccr2, Ccl9, Ccl8, Ccl7, Ccl6

Circadian entrainment

0.02853

Kcnj5, Fos, Adcy7, Gria1, Per1

However, the role of H19 in context of MFS is unclear and we

data also emphasized the importance of chemokine signalling, which is

believe it could be an interesting target to investigate.

crucial during MFS.33 However, the exact role of chemokine signalling

Moreover, we identified several genes to be commonly regulated

in MFS is still unclear. The other pathways from our GO analysis, such

between our RNA‐ sequencing dataset and a previously published

as focal adhesion, HCM and cardiac muscle contraction have also been

microarray datasets,15,21 suggesting the significance and importance of

implicated in MFS.58–60 Overall, our GO analysis suggests a specific

these genes in MFS. Furthermore, our approach identified several

and crucial role of identified genes and pathways that are relevant in

genes, such as Lrrc17, Mfap4, Ncam1, Gxylt2, Mfsd2a, Scube3, Ank2,

mgR/mgR mice.

Dsp, Myh10, Xirp, Smoc1, Chsy3, Adamts17, ppp1R36, Mylk2, Gucy1b3

In conclusion, our analysis expands the understanding of the

and Abcc9 to be significantly down‐regulated in mgR/mgR aortas, whose

pathobiology of Marfan disease progression. Our analysis revealed

regulation has not been previously related to MFS. However, we found

several genes previously unknown to be involved in aorta‐specific

Mylk2 protein levels to be induced in mgR/mgR mice, suggesting possi-

Marfan disease that may be important targets for designing more

ble posttranscriptional regulation of this particular gene.

appropriate therapeutic strategies for the treatment of MFS.

GO analysis of differentially regulated genes revealed relevant
pathways involved in cardiovascular biology and MFS, such as adrener-
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decreased the aortic dilatation and complications and improved the
clinical manifestations of MFS,51,52 emphasizing its crucial role in MFS.
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diomyocytes.

Furthermore, dilated cardiomyopathy in an MFS

patient was accompanied by chronic type A aortic dissection and right
atrial thrombus.54 We also found calcium signalling pathway to be
overrepresented in our dataset. It is known that calcium influx regu55

lates FBN1 expression.

Moreover, calcium channel blockers, are used

as a second line of therapy in 10%‐20% MFS patients who are intolerant to β‐blockers.56 However, calcium channel blockers have detrimental effects in MFS mice and are associated with an increased risk of
cardiovascular pathology in human MFS.57 All these data, highlight the
importance of our finding on calcium signalling and its implication in
MFS management. Apart from the above mentioned pathways, our
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